Organogenesis Names New CEO and CFO
Ticker: ORGO · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1661181
| Field | Detail |
|---|---|
| Company | Organogenesis Holdings INC. (ORGO) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, management
Related Tickers: ORGO
TL;DR
Organogenesis names Dr. Marc H. Miller as new CEO, effective immediately. Jennifer K. Chagnon to be new CFO on June 24.
AI Summary
Organogenesis Holdings Inc. announced on June 20, 2024, that its Board of Directors has appointed Dr. Marc H. Miller as Chief Executive Officer, effective immediately. Dr. Miller, who has served as interim CEO since March 2024, will also join the Board of Directors. The company also announced the appointment of Ms. Jennifer K. Chagnon as Chief Financial Officer, effective June 24, 2024. These appointments follow the departure of former CEO, Mr. Richard L. Thompson.
Why It Matters
The appointment of a permanent CEO and a new CFO signals a new leadership direction for Organogenesis, which could impact its strategic decisions and financial performance.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategic direction and operational execution, potentially impacting the company's performance.
Key Players & Entities
- Organogenesis Holdings Inc. (company) — Registrant
- Dr. Marc H. Miller (person) — Appointed Chief Executive Officer and Board Member
- Jennifer K. Chagnon (person) — Appointed Chief Financial Officer
- Richard L. Thompson (person) — Former CEO
- June 20, 2024 (date) — Date of earliest event reported
- March 2024 (date) — Start date of interim CEO role for Dr. Miller
- June 24, 2024 (date) — Effective date for CFO appointment
FAQ
Who has been appointed as the new CEO of Organogenesis Holdings Inc.?
Dr. Marc H. Miller has been appointed as the new Chief Executive Officer, effective immediately.
When is Jennifer K. Chagnon's appointment as CFO effective?
Ms. Jennifer K. Chagnon's appointment as Chief Financial Officer is effective June 24, 2024.
What was Dr. Miller's role prior to his permanent CEO appointment?
Dr. Miller served as interim CEO of Organogenesis Holdings Inc. since March 2024.
Who is being replaced by the new leadership appointments?
The appointments follow the departure of former CEO, Mr. Richard L. Thompson.
What other role will Dr. Marc H. Miller assume?
In addition to CEO, Dr. Marc H. Miller will also join the Board of Directors.
Filing Stats: 947 words · 4 min read · ~3 pages · Grade level 10.9 · Accepted 2024-06-21 16:12:31
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value ORGO Nasdaq Capital Marke
Filing Documents
- d826313d8k.htm (8-K) — 51KB
- d826313dex101.htm (EX-10.1) — 72KB
- 0001193125-24-165670.txt ( ) — 262KB
- orgo-20240620.xsd (EX-101.SCH) — 3KB
- orgo-20240620_lab.xml (EX-101.LAB) — 17KB
- orgo-20240620_pre.xml (EX-101.PRE) — 11KB
- d826313d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 2018 Equity Incentive Plan (as amended) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Organogenesis Holdings Inc. By: /s/ Lori Freedman Name: Lori Freedman Title: Chief Administrative and Legal Officer Date: June 21, 2024